Biomarker Analysis Services for Pancreatic Cancer
At Alfa Cytology, we offer specialized biomarker analysis services exclusively tailored for Pancreatic Cancer drug discovery and preclinical development. Our comprehensive biomarker panel is designed to support researchers and pharmaceutical partners in unraveling the complex pathophysiology of Pancreatic Cancer, accelerating the identification and validation of novel therapeutic targets. Please note that all services are strictly limited to research and preclinical stages of drug development and do not include any clinical diagnostic offerings.
Effective therapeutic intervention in Pancreatic Cancer begins with robust biomarker discovery and identification. Alfa Cytology’s biomarker discovery services provide a foundational step in the drug development pipeline, enabling the detection of molecular signatures associated with disease onset, progression, and therapeutic response. Our approach integrates high-throughput screening and systematic validation, employing state-of-the-art technologies to ensure the reproducibility and reliability of candidate biomarkers. Through iterative validation cycles, we support the transition of promising markers from discovery to preclinical evaluation.
Multi Omics: Our multi-omics strategy leverages cutting-edge genomics, transcriptomics, proteomics, and related technologies to achieve a comprehensive understanding of biological systems underlying Pancreatic Cancer. By integrating data across DNA, RNA, protein, and metabolite levels, we enable the identification of multi-dimensional biomarkers that reflect complex disease mechanisms. This holistic approach facilitates the elucidation of key pathways involved in DNA repair (e.g., BRCA1, BRCA2), cell signaling (KRAS, EGFR, ERBB2), cell adhesion (MUC1, MUC16, CEACAM5), and angiogenesis (VEGFA), all of which are relevant to Pancreatic Cancer pathophysiology.
Candidate Validation: Alfa Cytology employs rigorous validation strategies to confirm the association of candidate biomarkers with Pancreatic Cancer pathophysiology. Our preliminary screening processes utilize both in vitro and in vivo models to evaluate biomarker expression, functional relevance, and disease specificity. Criteria for prioritizing candidates include biological plausibility, reproducibility, analytical detectability, and alignment with known disease pathways. This systematic approach ensures that only the most promising biomarkers advance to downstream assay development.
Diverse Technological Platforms: We offer custom assay development capabilities across a suite of advanced technological platforms, adapting each to meet specific research requirements for Pancreatic Cancer studies. Our platforms include immunoassay systems, high-resolution mass spectrometry, flow cytometry, molecular diagnostics, and state-of-the-art histopathology and imaging modalities. Each platform is selected and optimized to maximize sensitivity, specificity, and throughput for the intended biomarker targets.
Immunoassays: Our laboratory develops and deploys ELISA, chemiluminescent, and multiplex immunoassays for quantitative and qualitative detection of protein biomarkers, including cell surface and secreted molecules relevant to Pancreatic Cancer.
Mass Spectrometry: We utilize LC-MS/MS and related mass spectrometry techniques for highly sensitive and specific quantification of proteins, peptides, and metabolites, supporting both targeted and untargeted biomarker discovery.
Flow Cytometry: Our flow cytometry platforms enable multi-parametric analysis of cell populations, allowing for the detection of surface markers (e.g., MUC1, MUC16) and intracellular signaling proteins in heterogeneous samples.
Molecular Diagnostics: We design and implement molecular assays, including PCR and DNA/RNA sequencing, to detect genetic alterations such as mutations in KRAS, BRCA1, BRCA2, TP53, and EGFR, which are pertinent to Pancreatic Cancer research.
Histopathology And Imaging: Immunohistochemistry and advanced imaging techniques are employed for spatial localization and quantification of biomarkers in tissue sections, supporting morphological and molecular characterization.
Rigorous Method Validation: All analytical methods undergo a rigorous validation process in accordance with established research guidelines. We assess key performance characteristics such as specificity, sensitivity, linearity, reproducibility, and robustness. Comprehensive quality control measures, including the use of reference standards, controls, and inter-assay comparisons, are implemented to ensure data integrity and reliability throughout the preclinical research process.
Our quantitative analysis capabilities encompass absolute and relative quantification of nucleic acids, proteins, and metabolites using validated platforms. We provide robust data analysis pipelines, statistical evaluation, and bioinformatics support to interpret biomarker expression patterns and their correlation with Pancreatic Cancer phenotypes.
Sample Analysis: Alfa Cytology processes a variety of sample types, including cell lines, xenograft tissues, primary tumor samples, and relevant biofluids. Each sample undergoes standardized protocols for collection, processing, and storage to preserve biomarker integrity. Analytical workflows are optimized for high sensitivity and specificity, with stringent quality measures at every step to ensure reproducibility and reliability of results.
High Throughput Capabilities: Our high-throughput analytical platforms enable multiplexed biomarker analysis, allowing simultaneous detection of multiple targets from limited sample volumes. This approach increases efficiency, reduces turnaround time, and conserves valuable preclinical samples, thereby accelerating the pace of Pancreatic Cancer research and therapeutic development.
| Gene Target | Biological Function | Application as a Biomarker |
|---|---|---|
| BRCA1 DNA repair associated (BRCA1) | BRCA1 (Breast Cancer 1, DNA repair associated) encodes a nuclear phosphoprotein that plays a critical role in maintaining genomic stability. BRCA1 is primarily involved in the repair of double-strand DNA breaks through homologous recombination. It forms complexes with other proteins, such as BARD1, and participates in various cellular processes, including cell cycle checkpoint control, transcriptional regulation, and chromatin remodeling. Loss or dysfunction of BRCA1 impairs DNA repair mechanisms, leading to increased genomic instability and susceptibility to tumorigenesis. | BRCA1 is used as a biomarker in the context of hereditary breast and ovarian cancer risk assessment. Germline mutations in BRCA1 are associated with a significantly increased risk of developing breast, ovarian, and other cancers. Detection of pathogenic BRCA1 variants is applied in genetic testing to identify individuals at elevated risk, inform surveillance strategies, and guide decisions regarding preventive interventions. Additionally, BRCA1 status may influence therapeutic choices, such as the use of PARP inhibitors in certain cancers. |
| BRCA2 DNA repair associated (BRCA2) | BRCA2 (Breast Cancer Type 2 Susceptibility Protein) is a key component in the maintenance of genomic stability through its role in homologous recombination, a critical DNA repair pathway. BRCA2 facilitates the recruitment and loading of RAD51 recombinase onto single-stranded DNA at sites of double-strand breaks, promoting error-free DNA repair. This function is essential for the accurate repair of DNA damage and the prevention of chromosomal aberrations. Loss or dysfunction of BRCA2 impairs homologous recombination, leading to increased genomic instability and a higher risk of malignant transformation. | BRCA2 is utilized as a biomarker primarily in the context of hereditary breast and ovarian cancer syndromes. Detection of pathogenic variants in the BRCA2 gene can inform risk assessment for breast, ovarian, prostate, and other cancers. BRCA2 mutation status is also used to guide clinical decision-making, including consideration of targeted therapies such as PARP inhibitors and determining eligibility for enhanced cancer surveillance programs. Additionally, BRCA2 status may provide prognostic information and influence treatment response in certain cancer types. |
| CEA cell adhesion molecule 5 (CEACAM5) | CEA cell adhesion molecule 5 (CEACAM5), also known as carcinoembryonic antigen (CEA), is a member of the immunoglobulin superfamily. It is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein primarily involved in cell adhesion. CEACAM5 mediates intercellular adhesion by binding homophilically (to itself) and heterophilically (to other CEACAM family members) on adjacent cells. It plays a role in modulating cell signaling, migration, and immune responses. Under physiological conditions, CEACAM5 is expressed at low levels in the apical surface of epithelial cells in the gastrointestinal tract and other mucosal tissues. | CEACAM5 is widely used as a tumor marker in clinical oncology. Its expression is elevated in a variety of carcinomas, particularly colorectal, gastric, pancreatic, lung, and breast cancers. Measurement of CEACAM5 levels in serum, plasma, or other body fluids is utilized to assist in monitoring disease progression, detecting recurrence, and evaluating response to therapy in patients with certain cancers. Immunohistochemical detection of CEACAM5 in tissue samples is also used to support pathological diagnosis and tumor characterization. |
| KRAS proto-oncogene, GTPase (KRAS) | KRAS (Kirsten rat sarcoma viral oncogene homolog) encodes a small GTPase that acts as a molecular switch in signal transduction pathways. In its active, GTP-bound state, KRAS transmits signals from cell surface receptors, such as the epidermal growth factor receptor (EGFR), to downstream effectors involved in cell proliferation, differentiation, and survival. KRAS cycles between an active GTP-bound form and an inactive GDP-bound form, a process regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). Mutations in KRAS can impair its intrinsic GTPase activity, resulting in constitutive activation of signaling pathways such as the MAPK/ERK and PI3K/AKT cascades. | KRAS is widely used as a molecular biomarker in oncology, particularly in the context of solid tumors such as colorectal, lung, and pancreatic cancers. The presence of specific activating mutations in KRAS, most commonly in codons 12, 13, and 61, is associated with resistance to certain targeted therapies, including anti-EGFR monoclonal antibodies in colorectal cancer. KRAS mutation status is therefore employed to guide therapeutic decision-making and to stratify patients for appropriate treatment options. Additionally, KRAS mutations are utilized in diagnostic and prognostic assessments, as well as in monitoring disease progression using circulating tumor DNA. |
| epidermal growth factor receptor (EGFR) | The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein that belongs to the receptor tyrosine kinase family. It is encoded by the EGFR gene and functions as a cell surface receptor for members of the epidermal growth factor family of extracellular protein ligands. Upon ligand binding, EGFR undergoes dimerization and autophosphorylation, which activates several downstream signaling cascades, including the RAS-RAF-MEK-ERK and PI3K-AKT pathways. These signaling events regulate key cellular processes such as proliferation, differentiation, survival, and migration. EGFR is widely expressed in epithelial tissues and plays a critical role in normal development and tissue homeostasis. | EGFR is utilized as a biomarker in various clinical and research contexts, particularly in oncology. Alterations in EGFR, such as gene mutations, amplifications, or protein overexpression, have been observed in several tumor types, including non-small cell lung cancer, colorectal cancer, and glioblastoma. Assessment of EGFR status can inform prognosis, guide the selection of targeted therapies (such as tyrosine kinase inhibitors and monoclonal antibodies), and monitor therapeutic response. EGFR testing is commonly performed using techniques such as immunohistochemistry, fluorescence in situ hybridization, and DNA sequencing. |
| erb-b2 receptor tyrosine kinase 2 (ERBB2) | ERBB2, also known as HER2, encodes a transmembrane receptor tyrosine kinase that is a member of the epidermal growth factor receptor (EGFR) family. The protein lacks a known ligand but forms heterodimers with other EGFR family members, leading to activation of intracellular signaling pathways such as the PI3K/AKT and MAPK pathways. These cascades regulate cell proliferation, survival, differentiation, and migration. ERBB2 is expressed at low levels in many normal tissues but is overexpressed or amplified in certain cancers, contributing to oncogenic signaling and tumorigenesis. | ERBB2 is widely used as a biomarker in oncology, particularly in breast and gastric cancers. Its overexpression or gene amplification is assessed to aid in diagnosis, prognostication, and selection of patients for targeted therapies such as monoclonal antibodies and tyrosine kinase inhibitors. Standardized assays, including immunohistochemistry and in situ hybridization, are employed to evaluate ERBB2 status in clinical samples. |
| mucin 1, cell surface associated (MUC1) | Mucin 1 (MUC1) is a transmembrane glycoprotein that is heavily glycosylated and expressed on the apical surface of most epithelial cells, including those of the respiratory, gastrointestinal, and genitourinary tracts. Its primary biological functions include providing a protective mucous barrier, participating in cell signaling, and contributing to cell adhesion. MUC1 modulates interactions between epithelial cells and their environment, and its cytoplasmic tail can interact with diverse signaling molecules, influencing processes such as cell proliferation, differentiation, and immune responses. Aberrant glycosylation and overexpression of MUC1 are frequently observed in various carcinomas, contributing to tumor progression and immune evasion. | MUC1 is utilized as a biomarker in several clinical and research contexts, most notably in the detection and monitoring of epithelial-derived cancers such as breast, ovarian, pancreatic, and lung cancers. Its overexpression and altered glycosylation patterns in tumor tissues, compared to normal tissues, facilitate its use in immunohistochemical analysis, serum assays (e.g., CA15-3 for breast cancer), and as a target for imaging and therapeutic strategies. MUC1 is also studied for its role in assessing prognosis and therapeutic response in oncology. |
| mucin 16, cell surface associated (MUC16) | MUC16 encodes a large transmembrane glycoprotein commonly referred to as CA125. It is a member of the mucin family, characterized by extensive O-glycosylation and a high molecular weight. MUC16 is primarily expressed on the cell surface of epithelial tissues, including the reproductive tract, respiratory tract, and ocular surface. Its biological functions include providing a protective mucous barrier, facilitating cell adhesion, and modulating immune responses. MUC16 can interact with mesothelin and other cell surface molecules, contributing to cell signaling and cellular interactions. In the context of malignancy, overexpression of MUC16 has been associated with altered cell adhesion, invasion, and immune evasion. | MUC16, most commonly detected as the CA125 antigen, is widely used as a biomarker in clinical settings, particularly for monitoring epithelial ovarian cancer. Elevated levels of CA125 in serum are associated with the presence and progression of ovarian cancer and are used to assess response to therapy and disease recurrence. In addition to ovarian cancer, increased CA125 levels may be observed in other malignancies and certain benign conditions, such as endometriosis and pelvic inflammatory disease. Its application as a biomarker is primarily based on its measurable presence in body fluids and its correlation with disease status. |
| tumor protein p53 (TP53) | Tumor protein p53 (TP53) encodes a transcription factor that plays a central role in regulating the cell cycle, DNA repair, apoptosis, and genomic stability. In response to various cellular stresses, such as DNA damage or oncogene activation, p53 can activate or repress the expression of target genes involved in cell cycle arrest, senescence, or programmed cell death (apoptosis). Through these mechanisms, p53 acts as a critical tumor suppressor, preventing the propagation of genetically damaged cells. Loss of normal p53 function, often through mutation, is associated with increased genomic instability and a higher risk of malignant transformation. | TP53 is frequently used as a biomarker in oncology due to the high prevalence of its mutations in a wide range of human cancers. Detection of TP53 mutations or abnormal p53 protein expression in tumor tissue can provide information about tumor development, prognosis, and, in some contexts, therapeutic response. Immunohistochemical assessment of p53 protein accumulation is commonly performed in diagnostic pathology to support tumor classification and evaluate potential molecular alterations. |
| vascular endothelial growth factor A (VEGFA) | Vascular endothelial growth factor A (VEGFA) is a key signaling protein involved in angiogenesis, the process by which new blood vessels form from pre-existing vasculature. VEGFA primarily acts on endothelial cells by binding to specific tyrosine kinase receptors, such as VEGFR-1 and VEGFR-2, promoting endothelial cell proliferation, migration, and survival. It also increases vascular permeability and plays a role in both physiological processes, such as embryonic development and wound healing, as well as in pathological conditions, including tumor growth and diabetic retinopathy. | VEGFA is utilized as a biomarker in various clinical and research contexts. Elevated levels of VEGFA in blood, tissue, or other biological samples have been associated with tumor angiogenesis and progression in several cancer types, including colorectal, lung, and breast cancers. Measurement of VEGFA can aid in assessing disease activity, prognosis, or response to anti-angiogenic therapies. Additionally, VEGFA is monitored in ocular fluids in conditions such as age-related macular degeneration and diabetic retinopathy, where it contributes to neovascularization. |
Explore Research Opportunities with Alfa Cytology. Our advanced biomarker research services for Pancreatic Cancer offer comprehensive support for exploratory and preclinical therapeutic development. We provide robust capabilities in biomarker discovery, validation, and assay development, utilizing a wide range of molecular, proteomic, and imaging platforms. Please note: all biomarkers discussed are research targets only and are not claimed as validated or mandatory for any application. Our work is strictly focused on preclinical research stages, maintaining scientific objectivity and adherence to the highest standards of exploratory science.
We invite you to engage with Alfa Cytology for collaborative discussions on exploratory biomarker research in Pancreatic Cancer. Our team is committed to advancing scientific knowledge and supporting preclinical research through objective, data-driven approaches. Contact us to explore how we can work together in the pursuit of novel biomarker insights.
Make Order
Experimental Scheme
Implementation
Conclusion
Solutions For Pancreatic Cancer
Alfa Cytology, a preclinical research solution provider, provides its clients with one-stop solutions to accelerate cancer therapeutics discovery and development.